HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phthalate draft report

This article was originally published in The Rose Sheet

Executive Summary

The National Toxicology Program Center for the Evaluation of Risks to Human Reproduction is requesting comments on the draft NTP brief on di-(2-ethylhexyl) phthalate. Comments are due July 5, according to a June 5 Federal Register 1notice. The draft brief evaluates the NTP's conclusions on the potential of DEHP to cause reproductive and developmental toxicity, and provides background information on the substance and findings of a CERHR expert panel. Among conclusions in the draft brief, NTP concurs with the expert panel that there is concern with effects on the development of the male reproductive tract for infants under one year of age. After the comment period and upon finalization, the NTP brief for DEHP will be included in the CERHR monograph for DEHP, center notes. NTP requested data on the ingredient last February, in preparation for a fall expert panel meeting (2"The Rose Sheet" Feb. 14, 2005, In Brief)...

You may also be interested in...

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

US/India Operation Intercepts Unapproved Drugs, Drug/Device Products

Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.

Two Companies, Two BARDA Contracts, Two Approaches To Coronavirus

Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts